Stockscreener 앱 받기
35.78
5.14%
-1.94
시간 외 거래:
35.08
-0.70
-1.96%
전일 마감가:
$37.72
열려 있는:
$38.05
하루 거래량:
783.88K
Relative Volume:
0.56
시가총액:
$1.22B
수익:
$55.63M
순이익/손실:
$-158.10M
주가수익비율:
-4.2493
EPS:
-8.4202
순현금흐름:
$-203.94M
1주 성능:
-13.09%
1개월 성능:
-46.90%
6개월 성능:
-57.40%
1년 성능:
-34.90%
1일 변동 폭
$35.61
$38.05
1주일 범위
$35.61
$40.98
52주 변동 폭
$33.40
$109.00
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
35.78 | 1.22B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-12 | 개시 | Leerink Partners | Outperform |
| 2026-10-12 | 개시 | UBS | Neutral |
| 2026-10-09 | 개시 | Raymond James | Mkt Perform |
| 2026-08-21 | 재개 | JP Morgan | Neutral |
| 2026-07-22 | 개시 | Canaccord Genuity | Buy |
| 2026-03-24 | 개시 | Wedbush | Neutral |
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Nektar Therapeutics (NKTR) Could Be 72% Undervalued On New Rezpegaldesleukin Data - Simply Wall Street
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail
Nektar Therapeutics Initiated at Neutral by UBS - Moomoo
UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53 - Moomoo
Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te - GuruFocus
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha
Nektar Therapeutics Price Target Announced at $53.00/Share by UBS - Moomoo
Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case - Yahoo Finance
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - marketscreener.com
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - Yahoo Finance
UBS initiates Nektar Therapeutics stock at Neutral on catalyst timing By Investing.com - Investing.com Nigeria
Raymond James Initiates Nektar Therapeutics at Market Perform - Yahoo Finance
Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR) - Simply Wall Street
Nektar Therapeutics stock faces a cash runway into 2028 - AD HOC NEWS
Is Nektar Therapeutics (NKTR) Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans? - Simply Wall Street
Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance Singapore
Nektar Therapeutics (NKTR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang - Yahoo Finance
Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response - Streetwise Reports
Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk - Investing.com
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo
Nektar Therapeutics (NKTR) Shareholder/Analyst CallSlideshow (NASDAQ:NKTR) 2026-10-03 - Seeking Alpha
Nektar Therapeutics Company Profile & Introduction - Moomoo
Two Seas Capital LP Adds Nektar Therapeutics (NKTR) -- Shares Look 766% Overvalued on GF Value - GuruFocus
Nektar Therapeutics Stock Price Forecast. Should You Buy NKTR? - StockInvest.us
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (NKTR) - Seeking Alpha
HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target - TradingView
Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions - Simply Wall Street
Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata - The Clinical Trial Vanguard
Jefferies sets $150 target for Nektar Therapeutics amid promising alopecia drug data despite stock drop. - Pluang
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Yahoo Finance
Jefferies Analyst Defends Nektar Therapeutics (NKTR) Amid 21% St - GuruFocus
Why This Biotech Took A 21% Hit On Promising Alopecia Results - Investor's Business Daily
Nektar Therapeutics (NKTR) Shares Drop After Rezpegaldesleukin T - GuruFocus
William Blair Reaffirms Outperform on Nektar Therapeutics (NKTR) Amid Rezpeg Data Advances - GuruFocus
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo! Finance Canada
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? - Barron's
Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023 -- Data Talk - Moomoo
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial - Yahoo Finance
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 - PR Newswire
Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment - TradingView
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK) - The Globe and Mail
/UPDATE -- Nektar Therapeutics/ - Yahoo Finance
Asset turnover of Nektar Therapeutics – HAN:ITH0 - TradingView
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - webull.com
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors - Yahoo Finance
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case? - Yahoo Finance
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - Simply Wall Street
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
넥타테라퓨틱스 주식 (NKTR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Officer |
Aug 18 '26 |
Proposed Sale |
71.98 |
186 |
13,388 |
0 |
| ROBIN HOWARD W | Officer |
Aug 18 '26 |
Proposed Sale |
71.98 |
418 |
30,087 |
0 |
| ROBIN HOWARD W | President & CEO |
Aug 18 '26 |
Sale |
71.98 |
418 |
30,088 |
54,627 |
| Zalevsky Jonathan | Chief R&D Officer |
Jun 30 '26 |
Sale |
70.00 |
5,681 |
397,670 |
9,756 |
| JONATHAN ZALEVSKY | Officer |
Jun 30 '26 |
Proposed Sale |
65.39 |
5,681 |
371,481 |
0 |
| ROBIN HOWARD W | President & CEO |
Jun 17 '26 |
Sale |
61.19 |
10,000 |
611,880 |
55,045 |
| ROBIN HOWARD W | Officer |
Jun 17 '26 |
Proposed Sale |
60.27 |
10,000 |
602,700 |
0 |
| ROBIN HOWARD W | Officer |
Jun 16 '26 |
Proposed Sale |
60.96 |
10,000 |
609,600 |
0 |
| ROBIN HOWARD W | President & CEO |
Jun 16 '26 |
Sale |
60.32 |
10,000 |
603,176 |
65,045 |
| Zalevsky Jonathan | Chief R&D Officer |
Jun 15 '26 |
Sale |
60.71 |
5,538 |
336,212 |
15,437 |
6.12%
0.14%
자본화:
|
볼륨(24시간):